{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jontvedt Jorgensen M"],"funding":["Norges Forskningsråd","Helse Sør-Øst RHF"],"pagination":["669623"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8299478"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11"],"pubmed_abstract":["<h4>Introduction</h4>Eicosanoids and intracellular signaling pathways are potential targets for host-directed therapy (HDT) in tuberculosis (TB). We have explored the effect of cyclooxygenase 2 inhibitor (COX-2i) treatment on eicosanoid levels and signaling pathways in monocytes.<h4>Methods</h4>Peripheral blood mononuclear cells isolated from TB patients included in a randomized phase I clinical trial of standard TB treatment with (n=21) or without (n=18) adjunctive COX-2i (etoricoxib) were analyzed at baseline, day 14 and day 56. Plasma eicosanoids were analyzed by ELISA and liquid chromatography-mass spectrometry (LC-MS), plasma cytokines by multiplex, and monocyte signaling by phospho-flow with a defined set of phospho-specific antibodies.<h4>Results</h4>Lipoxygenase (LOX)-derived produ"],"journal":["Frontiers in cellular and infection microbiology"],"pubmed_title":["Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients."],"pmcid":["PMC8299478"],"funding_grant_id":["GlobVac no 234493"],"pubmed_authors":["Layre E","Aass HCD","Mortensen R","Tonby K","Jenum S","Tasken K","Dyrhol-Riise AM","Jontvedt Jorgensen M","Kvale D","Nore KG","Nigou J"],"additional_accession":[]},"is_claimable":false,"name":"Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.","description":"<h4>Introduction</h4>Eicosanoids and intracellular signaling pathways are potential targets for host-directed therapy (HDT) in tuberculosis (TB). We have explored the effect of cyclooxygenase 2 inhibitor (COX-2i) treatment on eicosanoid levels and signaling pathways in monocytes.<h4>Methods</h4>Peripheral blood mononuclear cells isolated from TB patients included in a randomized phase I clinical trial of standard TB treatment with (n=21) or without (n=18) adjunctive COX-2i (etoricoxib) were analyzed at baseline, day 14 and day 56. Plasma eicosanoids were analyzed by ELISA and liquid chromatography-mass spectrometry (LC-MS), plasma cytokines by multiplex, and monocyte signaling by phospho-flow with a defined set of phospho-specific antibodies.<h4>Results</h4>Lipoxygenase (LOX)-derived produ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-08T18:49:37.048Z","creation":"2022-02-10T23:41:51.099Z"},"accession":"S-EPMC8299478","cross_references":{"pubmed":["34307194"],"doi":["10.3389/fcimb.2021.669623"]}}